Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2024Second Quarter 2024 • Total revenue increased 12 per cent, 11 per cent at constant exchange rates, (CER)1, to SEK 5,442 M (4,872) • Haematology revenue increased 13 per cent at CER to SEK 3,866 M (3,430), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® excluding sales to China of SEK 928 M (567), sales of Vonjo® of SEK 347 M (36) and sales of Aspaveli®/Empaveli® of SEK 251 M (144) • Immunology revenue increased 7 per cent at